378 related articles for article (PubMed ID: 1356580)
1. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
Engber TM; Boldry RC; Kuo S; Chase TN
Brain Res; 1992 May; 581(2):261-8. PubMed ID: 1356580
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
Engber TM; Marin C; Susel Z; Chase TN
Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
[TBL] [Abstract][Full Text] [Related]
3. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid dynorphin and enkephalin immunostaining in 6-hydroxydopamine lesioned rats.
Jiang HK; Wang JY
Chin J Physiol; 1991; 34(4):413-25. PubMed ID: 1687937
[TBL] [Abstract][Full Text] [Related]
4. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
Hu XT; Brooderson RJ; White FJ
Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
[TBL] [Abstract][Full Text] [Related]
5. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
Jiang HK; McGinty JF; Hong JS
Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
[TBL] [Abstract][Full Text] [Related]
6. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
7. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat.
Taylor MD; de Ceballos ML; Jenner P; Marsden CD
Biochem Pharmacol; 1991 May; 41(9):1385-91. PubMed ID: 1673340
[TBL] [Abstract][Full Text] [Related]
9. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.
Singh NA; Bush LG; Gibb JW; Hanson GR
Brain Res; 1992 Feb; 571(2):260-4. PubMed ID: 1351780
[TBL] [Abstract][Full Text] [Related]
10. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
LaHoste GJ; Yu J; Marshall JF
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of release of acetylcholine in the striatum in mice following continuous exposure to selective D1 and D2 dopaminergic agonists.
Wang HY; Zhou LW; Friedman E; Weiss B
Neuropharmacology; 1993 Jan; 32(1):85-91. PubMed ID: 8094235
[TBL] [Abstract][Full Text] [Related]
13. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
Pollack AE; Yates TM
Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
[TBL] [Abstract][Full Text] [Related]
14. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
Sivam SP; Breese GR; Krause JE; Napier TC; Mueller RA; Hong JS
J Neurochem; 1987 Nov; 49(5):1623-33. PubMed ID: 2889804
[TBL] [Abstract][Full Text] [Related]
15. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Paul ML; Graybiel AM; David JC; Robertson HA
J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
[TBL] [Abstract][Full Text] [Related]
16. Reevaluation of the two-component hypothesis for turning behaviour by manipulating activities in the striatum and the nucleus accumbens of intact rats.
Saigusa T; Koshikawa N; Kitamura M; Kobayashi M
Eur J Pharmacol; 1993 Jun; 237(2-3):161-8. PubMed ID: 8103458
[TBL] [Abstract][Full Text] [Related]
17. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
Chen JF; Aloyo VJ; Weiss B
Neuroscience; 1993 Jun; 54(3):669-80. PubMed ID: 8101360
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
Pollack AE; Wooten GF
Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D2 receptor control of pallidal fos expression: comparisons between intact and 6-hydroxydopamine-treated hemispheres.
Marshall JF; Cole BN; LaHoste GJ
Brain Res; 1993 Dec; 632(1-2):308-13. PubMed ID: 7908600
[TBL] [Abstract][Full Text] [Related]
20. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.
Bronstein DM; Ye H; Pennypacker KR; Hudson PM; Hong JS
Brain Res Mol Brain Res; 1994 May; 23(3):191-203. PubMed ID: 7914658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
